Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells

Lina BAI; Ying LIU; Chunxiao TANG; Hongxin PIAO; Zhenhua LIN; Wanshan YANG; Aihua JIN

doi:10.3969/j.issn.1001-5256.2022.12.020

Volume 38 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(12): 2793-2801

PDF( 6790 KB)

Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells

DOI: 10.3969/j.issn.1001-5256.2022.12.020

1.
Cancer Research Center, School of Medicine, Yanbian University, Yanji, Jilin 133000, China
2a.
Department of Infectious Diseases, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China
2b.
Department of Gastroenterology, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

Research funding:

Science and Technology Research Project of Jilin Province Department of Education (JJKH20220554KJ);

Heatth Science and Technology Capacity Improvement Project of Jilin Province (2021JC063)

More Information

Corresponding author: JIN Aihua, drjinah@163.com (ORCID: 0000-0002-3405-8097)
Received Date: 2022-05-26
Accepted Date: 2022-07-20
Published Date: 2022-12-20

Abstract

Abstract

Objective To investigate the effect of carrimycin on the biological function of pancreatic cancer cells. Methods Pancreatic cancer cell lines MIA PaCa-2, BxPC-3, Panc-1, and PATU 8988 were treated with carrimycin at concentrations of 0 (control group), 2, 4, 8, and 16 μmol/L for 24, 48, and 72 hours. MTT assay was used to measure cell viability; EdU cell proliferation assay was used to observe the effect of carrimycin on DNA replication of pancreatic cancer cells; colony formation assay was used to observe the effect of carrimycin on the proliferation of pancreatic cancer cells; flow cytometry was used to analyze the effect of carrimycin on the cell cycle of pancreatic cancer cells; wound healing assay was used to analyze the effect of carrimycin on the migration of pancreatic cancer cells; Western blot was used to measure the expression levels of the markers such as epithelial-mesenchymal transition (EMT) and cell cycle-dependent protein kinase inhibitor 1A (P21); immunofluorescence assay were used to measure the expression levels of EMT-related markers. An analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results Compared with the control group, carrimycin significantly inhibited the proliferative activity of MIA PaCa-2, BxPC-3, Panc-1, and PATU 8988 cells in a concentration- and time-dependent manner (all P < 0.01); carrimycin at concentrations of 4, 8, and 16 μmol/L significantly reduced DNA replication in MIA PaCa-2 cells (t=2.378, 4.984, and 18.970, all P < 0.05) and BxPC-3 cells (t=4.879, 6.089, and 9.521, all P < 0.01); after treatment with carrimycin at concentrations of 4, 8, and 16 μmol/L, colony formation ability significantly decreased with the increase in drug concentration in MIA PaCa-2 cells (t=5.889, 11.240, and 15.840, all P < 0.001) and BxPC-3 cells (t=6.717, 15.800, and 18.850, all P < 0.001). After treatment with carrimycin at concentrations of 4, 8, and 16 μmol/L, there was a significant increase in the proportion of cells in G1 phase in MIA PaCa-2 cells (t=9.071, 12.280, and 19.360, all P < 0.0001) and BxPC-3 cells (t=3.061, 4.962, and 8.868, all P < 0.05), and there was a significant reduction in the proportion of cells in S phase in MIA PaCa-2 cells (t=2.316, 4.165, and 5.562, all P < 0.05) and BxPC-3 cells (t=2.424, 3.264, and 5.744, all P < 0.05). Western blot further demonstrated that compared with the control group, the expression level of the cell cycle-related protein P21 gradually increased with the increase in the concentration of carrimycin in MIA PaCa-2 cells (t=5.437, 6.453, and 8.799, all P < 0.001) and BxPC-3 cells (t=25.130, 44.750, and 52.960, all P < 0.000 1). Wound healing assay showed that after treatment for 12, 24, and 48 hours, carrimycin at concentrations of 0, 4, 8, and 16 μmol/L significantly reduced the lateral migration of MIA PaCa-2 cells (all P < 0.05) and BxPC-3 cells (all P < 0.05). Western blot showed that compared with the control group, carrimycin treatment at concentrations of 4, 8, and 16 μmol/L significantly upregulated the expression of the epithelial marker E-cadherin in MIA PaCa-2 cells (t=2.388, 4.899, and 5.819, all P < 0.05) and BxPC-3 cells (t=2.533, 5.836, and 6.774, all P < 0.05) and significantly downregulated the expression of the interstitial marker Snail in MIA PaCa-2 cells (t=12.440, 14.830, and 16.800, all P < 0.000 1) and BxPC-3 cells (t=5.039, 5.893, and 7.725, all P < 0.01), and it also significantly downregulated the expression of the interstitial marker Vimentin in MIA PaCa-2 cells (t=3.105, 7.752, and 11.200, all P < 0.05) and BxPC-3 cells (t=2.555, 4.883, and 9.153, all P < 0.05). Conclusion Carrimycin can effectively inhibit the proliferation, migration, and EMT process of pancreatic cancer cells, thereby exerting an antitumor biological activity.
- Pancreatic Neoplasms,
- Cell Proliferation,
- Cell Movement,
- Epithelial-Mesenchymal Transition

FullText(HTML)

References(18)

References

[1]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2]	General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(5): 1006-1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007. 国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5): 1006-1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007.
[3]	ZHU H, WEI M, XU J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications[J]. Mol Cancer, 2020, 19(1): 49. DOI: 10.1186/s12943-020-01167-9.
[4]	HAN A, XU R, LIU Y, et al. HSDL2 acts as a promoter in pancreatic cancer by regulating cell proliferation and lipid metabolism[J]. Onco Targets Ther, 2021, 14: 435-444. DOI: 10.2147/OTT.S287722.
[5]	NEOPTOLEMOS JP, KLEEFF J, MICHL P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 333-348. DOI: 10.1038/s41575-018-0005-x.
[6]	HAO TY, HE WQ. Advances in metabolic engineering of macrolide antibiotics[J]. Chin J Biotech, 2021, 37(5): 1737-1747. DOI: 10.13345/j.cjb.200686. 郝天怡, 赫卫清. 大环内酯类抗生素代谢工程的研究进展[J]. 生物工程学报, 2021, 37(5): 1737-1747. DOI: 10.13345/j.cjb.200686.
[7]	JIN Y, ZUO HX, LI MY, et al. Anti-tumor effects of carrimycin and monomeric isovalerylspiramycin I on hepatocellular carcinoma in vitro and in vivo[J]. Front Pharmacol, 2021, 12: 774231. DOI: 10.3389/fphar.2021.774231.
[8]	LIANG SY, ZHAO TC, ZHOU ZH, et al. Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo[J]. Transl Oncol, 2021, 14(6): 101074. DOI: 10.1016/j.tranon.2021.101074.
[9]	ZHANG XY, HAO RH, LIU F, et al. Progress in Application of Rapamycin in Tumor Treatment[J]. Food Drug, 2018, 20(1): 65-70. DOI: 10.3969/j.issn.1672-979X.2018.01.016. 张晓元, 郝荣华, 刘飞, 等. 雷帕霉素在肿瘤治疗方面研究进展[J]. 食品与药品, 2018, 20(1): 65-70. DOI: 10.3969/j.issn.1672-979X.2018.01.016.
[10]	EDELMAN MJ, SHVARTSBEYN M. Epothilones in development for non—small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance[J]. Clin Lung Cancer, 2012, 13(3): 171-180. DOI: 10.1016/j.cllc.2011.02.005.
[11]	GIANNAKAKOU P, GUSSIO R, NOGALES E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells[J]. Proc Natl Acad Sci U S A, 2000, 97(6): 2904-2909. DOI: 10.1073/pnas.040546297.
[12]	LI YL, SUN J, HU X, et al. Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway[J]. J Cancer Res Clin Oncol, 2016, 142(11): 2281-2289. DOI: 10.1007/s00432-016-2236-y.
[13]	CUI J, ZHOU J, HE W, et al. Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by Isovalerylspiramycin I[J]. J Exp Clin Cancer Res, 2022, 41(1): 126. DOI: 10.1186/s13046-022-02350-0.
[14]	LIU Y, QUAN Y. Relationship between inflammatory microenvironment and epithelial-mesenchymal transition and its significance in pancreatic carcinoma[J]. Chin J Clin Res, 2018, 31(12): 1619-1623. DOI: 10.13429/j.cnki.cjcr.2018.12.006. 刘宇, 全颖. 胰腺癌炎性微环境与细胞上皮间质转化的关系及意义[J]. 中国临床研究, 2018, 31(12): 1619-1623. DOI: 10.13429/j.cnki.cjcr.2018.12.006.
[15]	BAKIR B, CHIARELLA AM, PITARRESI JR, et al. EMT, MET, plasticity, and tumor metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776. DOI: 10.1016/j.tcb.2020.07.003.
[16]	YEUNG KT, YANG J. Epithelial-mesenchymal transition in tumor metastasis[J]. Mol Oncol, 2017, 11(1): 28-39. DOI: 10.1002/1878-0261.12017.
[17]	KONG HR, DAI SJ, CHEN H, et al. α-solanine inhibits epithelial-mesenchymal transition in trichostatin A-resistant human pancreatic cancer cells through the WNT signaling pathway[J]. J Hepatopancreatobiliary Surg, 2020, 32(2): 89-96. DOI: 10.11952/j.issn.1007-1954.2020.02.006. 孔鸿儒, 戴胜杰, 陈豪, 等. α-龙葵碱通过WNT信号通路抑制曲古抑菌素A-耐药人胰腺癌细胞的上皮-间质转化进程[J]. 肝胆胰外科杂志, 2020, 32(2): 89-96. DOI: 10.11952/j.issn.1007-1954.2020.02.006.
[18]	LIU JB, QI M, LI QQ, et al. The mechanism of cordycepin in inhibition of pancreatic cancer stem cells proliferation and metastasis[J]. Acta Pharm Sin, 2017, 52(9): 1404-1409. DOI: 10.16438/j.0513-4870.2017-0353. 刘建兵, 戚梦, 李巧琪, 等. 虫草素抑制胰腺癌干细胞增殖及转移的机制研究[J]. 药学学报, 2017, 52(9): 1404-1409. DOI: 10.16438/j.0513-4870.2017-0353.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (1582) PDF downloads(61)

Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells

DOI: 10.3969/j.issn.1001-5256.2022.12.020

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells

DOI: 10.3969/j.issn.1001-5256.2022.12.020

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content